Clinical Trials Directory

Trials / Recruiting

RecruitingNCT07354477

Single-site Pilot Study Evaluating the Effect of QLS-111 Ophthalmic Solution on Posterior Perfusion and Vessel Dilation

An Exploratory, Pilot, Single-site Study to Evaluate the Effect of QLS-111 Ophthalmic Solution on Posterior Perfusion and Vessel Dilation

Status
Recruiting
Phase
Phase 2
Study type
Interventional
Enrollment
14 (estimated)
Sponsor
Qlaris Bio, Inc. · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Pilot, single-site, prospective study of QLS-111 0.015 % in subjects with NPDR, OAG or NTG

Detailed description

Pilot, single-site, prospective study of BID OU dosing of QLS-111 0.015 % for 7 days followed by QLS-111 0.075% BID OU in subjects with NPDR, OAG or NTG. Both eyes (OU) will be dosed. The study is comprised of 4 visits including Screening/Baseline visit, 2 Treatment Period visits over 14 days of IP dosing, and a Post-Treatment visit.

Conditions

Interventions

TypeNameDescription
DRUGQLS-111 Ophthalmic Solution (0.015%)QLS-111 (0.015%) administered BID for 7 days OU.
DRUGQLS-111 Ophthalmic Solution (0.075%)QLS-111 (0.075%) administered BID for 7 days OU. Follows the 7 days where QLS-111 (0.015%) is administered.

Timeline

Start date
2026-02-20
Primary completion
2026-06-01
Completion
2026-06-01
First posted
2026-01-21
Last updated
2026-02-24

Locations

1 site across 1 country: United States

Regulatory

Source: ClinicalTrials.gov record NCT07354477. Inclusion in this directory is not an endorsement.